Together, these data highlight that activated TIGIT+DNAM-1+ T cells are present in G-CSF–mobilized PBSC grafts from patients with MM and as such TIGIT represents a logical immunotherapeutic target in combination with ASCT. This evidence concerns the gene CD226 and Miyoshi myopathy.